DAVID M. MOTT - 10 Jun 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Issuer symbol
NVAX
Transactions as of
10 Jun 2022
Net transactions value
$0
Form type
4
Filing time
14 Jun 2022, 17:09:51 UTC
Previous filing
10 Jun 2022
Next filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Stock Option (Right to Buy) Award $0 +4,600 $0.000000 4,600 10 Jun 2022 Common Stock 4,600 $40.62 Direct F1
transaction NVAX Restricted Stock Units Award $0 +3,100 $0.000000 3,100 10 Jun 2022 Common Stock 3,100 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan") will vest one (1) year from the June 10, 2022 grant date (the "Grant Date") subject to continued service on the Company's Board of Directors through the vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock.
F3 One hundred percent (100%) of the RSUs subject to this grant under the Plan will vest one (1) year from the Grant Date subject to continued service on the Company's Board of Directors through the vesting date.